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Abstract: The formation of extracellular aggregates built up by deposits 
of β-amyloid (Aβ) is a hallmark of Alzheimer's disease (AD). Curcumin has 
been reported to display anti-amyloidogenic activity, not only by 
inhibiting the formation of new Aβ aggregates, but also by disaggregating 
existing ones. However, the uptake of Curcumin into the brain is severely 
restricted by its low ability to cross the blood-brain barrier (BBB). 
Therefore, novel strategies for a targeted delivery of Curcumin into the 
brain are highly desired. Here, we encapsulated Curcumin as active 
ingredient in PLGA (polylactide-co-glycolic-acid) nanoparticles (NPs), 
modified with g7 ligand for BBB crossing. We performed in depth analyses 
of possible toxicity of these NPs, uptake, and, foremost, their ability 
to influence Aβ pathology in vitro using primary hippocampal cell 
cultures. Our results show no apparent toxicity of the formulated NPs, 
but a significant decrease of Aβ aggregates in response to Curcumin 
loaded NPs. We thus conclude that brain delivery of Curcumin using BBB 
crossing NPs is a promising future approach in the treatment of AD. 
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 Reviewer #1: Barbara and co-workers report a study on the encapsulation of curcumin in polymeric 
nanoparticles modified with a glycopeptide. They propose this formulation as an approach to target CUR to 
the CNS. The study comprises the physicochemical characterization and in vitro studies on toxicity and 
effects on amyloid beta aggregates. However, in our opinion the manuscript needs a revision regarding 
some aspects, as detailed below: 
 
1) Please, improve the introduction, taking into account previous studies with nanospheres and 
nanocapsules containing curcumin proposed for treament of AD. 
We improved as suggested by the reviewer.  
 
2) Novelty of the study is not clear in the introduction and objective. 
 
Notwithstanding the encapsulation of curcumin into nanoparticles is a well-known aspect, in this study we 
evaluated the possibility to stabilize therapeutic amounts of drug into engineered nanoparticles specifically 
designed to cross the BBB. We applied our own validated methodology by formulating g7-NPs using pre-
formulation approach. Here, as a first step for the future application of the new loaded nanoparticles, we 
reported a technological characterization of the systems, but most of all the demonstration of the absence 
of toxicity and ability to reduce the aggregation of -amyloid in vitro. We therefore improved the 
introduction by focusing on the objective of the study.  
 
3) Was the amount of cryoprotectant not considered in the calculation of the yield? Why? 
Trehalose was added to the formulation as cryoprotectant. More in detail, we added Trehalose at the end 
of the formulation and purification processes and immediately before the freeze dry process with the aim 
to protect nanoparticles from aggregation and possible deconstruction. Based on this technological 
process, the yield of formulation was calculated considering only the component used during the 
formulation process (PLGA and Cur), thus excluding both surfactant and trehalose. We corrected the 
formula in the text as suggested by the reviewer. 
 
4) Do the particle size values represent the behavior before or after the freeze-drying process? How were 
the samples diluted after the drying process? Comparison between the particle size properties before and 
after the freeze-drying process is missing. 
Data reported refers to value obtained before the freeze-drying process. We thanks the reviewer for the 
comment, and, for a more complete characterization, we added a complete table with data obtained after 
suspension of the freeze-drying NPs powder in distilled water.  
We improve both Fig.1 legend and method section, for a complete description of samples.  
 
5) Could the loading capacity and encapsulation efficiency be affected by the presence of CUR crystals 
(including nanocrystals) in the Freeze-dried powder? In other words, as CUR has a very low aqueous 
solubility, could it precipitate during the formulation? How can the authors refute the hypothesis of 
simultaneous presence of CUR crystals and nanoencapsulated CUR in the powders? 
 
*Response to Reviewers
As reported by the reviewer, the low water solubility of curcumin could induce a precipitation of the not 
encapsulated drug during the formulation. In our protocol, the presence of surfactant (PVA at 1% v/v) 
assures that the part of drug, which remains outside from the nanoparticles, to stay complexed with PVA 
and perfectly in solution. Based on this observation, we did not observe any precipitate (yellow powder 
related to crystals of curcumin which should rapidly precipitate) during the formulation or during the 
washing process. PCS data of the formulation in the post purification step or in the post freeze-drying step 
in fact described the presence of monomodal population excluding the presence of crystals.    
6) Were the sink conditions considered during the in vitro drug release analysis? Could the sustained phase 
of the release profile be explained by any saturation of the release medium? How much the delivery of CUR 
from the NPs (Fig. 1D) is different from the release from a bulk suspension? 
The release study was carried out considering the sink conditions. Curcumin has a very low water solubility 
(1-10 µg/mL, Jagannathan, R., et al.,  2012. Temperature-dependent Spectroscopic evidences of curcumin in aqueous 
medium: a mechanistic study of its solubility and stability. J. Phys. Chem. B 116: 14533−14540), thus reaching the 
sink condition in buffer resulted very difficult, thus requiring a large volume of water phase.  
In this study, we chose to incubate loaded NPs in a medium composed by PBS and FBS (50%v/v), in order to 
mimic the physiological conditions. In this case, the presence of large amounts of proteins both produces a 
condition similar in vivo one and acts as a “carrier” for curcumin, released from nanoparticles thus 
increasing Curcumin solubility in the release medium and insuring sink conditions. Based on this fact, the 
conditions used in this study match the sink condition for the study of the release.  
In absence of a dialyses bag or any other physical device commonly used to study the release of a drug 
from a nanoparticles, we decided not to evaluate the diffusion of Curcumin from bulk.  
In this case, nanoparticles are not also a delivery system, but a strategy to improve solubility of the drug 
that on the contrary, without encapsulation, rapidly precipitates in water at the concentrations used in this 
study, thus quickly being not administrable. Based on this evidences, we think that the release of Cur from 
the nanopartilces should be considered as an objective data, not comparable with the release from the 
bulk.  
 
7) Comparison between the encapsulated CUR and its non-encapsulated form is missing in the discussion 
and conclusion. What are the conclusions about the advantages of CUR encapsulation? The improved 
aqueous solubility and stability have been widely described for nanoencapsulated drugs and substances 
and it is not a novelty. Conclusion should be improved to highlight the novel contribution of the paper to 
the area. How can you conclude about the superior performance of the encapsulated CUR compared with 
CUR? 
We improved the discussion conclusion section by following the suggestions of the reviewer. 
 
8) Check for typos (proprieties, page 16). 
 
Thanks, we checked the typos and corrected 
 
Reviewer #2: This manuscript from Barbara et al. entitled "Targeted disruption of Amyloid beta aggregates 
by novel Curcumin loaded Nanoparticles International Journal of Pharmaceutics" describes the use of 
curcumin loaded particles to impede the formation of amyloid deposits. The authors usepreviously 
developped PLGA nanoparticles conjugated with a peptide supposed to target the blood brain barrier and 
facilitate the translocation into the brain. The different tests presented presented tend to demonstrate that 
the particles have a significant effect in decreasing amyloid production in vitro and present low cellular 
toxicity at different cellular levels. 
 
Overall, the manuscript is well presented with a lot of relevant experimental data. The approach used by 
the authors has been reported extensively but the study provides an interesting comprehensive view of the 
subtle mechanisms involved in curcumin therapeutical efficacy. 
 
My main concerns are related to the characterization of the particles 
The tests used to confirm the presence of the peptide at the surface of the particle is absolutely 
inconclusive. The authors should have performed a high resolution scan or even better, an NMR of the 
particles.  
The presence of g7 onto the surface of nanoparticles was extensively demonstrated in previous studies. As 
previously reported, the use of a preformulative approach (in which g7 was conjugated to PLGA before the 
nanoparticles formulation) assure the g7, which is the hydrophilic moiety of the conjugated polymer, to be 
exposed on the surface, at the interface with water. In this way, the exposed peptide was able to mediate 
the BBB passage of PLGA NPs as demonstrated by pharmacological evidences (Tosi G, et al., 2011.  
Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. 
Nanomedicine 6:423-36., Salvalaio M, et al., 2016. Targeted Polymeric Nanoparticles for Brain Delivery of 
High Molecular Weight Molecules in Lysosomal Storage Disorders. PLoS One. 11:e0156452. Valenza M, et 
al., 2015. Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's 
disease mice. EMBO Mol Med. 7:1547-64. Tosi G, et al., 2007. Targeting the central nervous system: in vivo 
experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control 
Release. 122:1-9).  
As ESCA is one of the most versatile tools in identifying the chemical species on a surface, we used this 
protocol for surface characterization in order to confirm the g7 exposure on the surface of Curcumin loaded 
nanoparticles.  
ESCA is a surface analysis technique that provides elemental and binding energy information about a 
material's surfaces and interfaces. Characterized by an average depth of measurement of approximately 5 
nm. (Vickerman, JC., et al., The Principal Techniques, 2nd Edition. Chapter 3. Electron Spectroscopy for 
Chemical Analysis) 
In this study, we reported ESCA characterization of unloaded and unmodified (NPs), unloaded and modified 
(g7-NPs) and loaded and modified nanoparticles (g7-NPs-Cur). Both sample were analyzed as dehydrated 
nanoparticles on an inert support. All the operations for sample preparation were carried out in a laminar 
flow hood to prevent any kind of contamination. Based on the assumed that all components of 
nanoparticles (PLGA, PVA and curcumin) are composed of C, H and O the signal typical of N should be 
related to the peptide exposed on the surface. As reported in results section, N signal was clearly detected 
in both g7-NPs and g7-NPs-Cur. 
The presence of N signal assure that i) g7 is exposed on surface; ii) unless curcumin is partially exposed on 
the surface it not completely covered the peptide on nanoparticles surface.  
We implemented the section “formulation and characterization of novel nanoparticles”. 
 
100% of release in less than 5 h seems really fast for nanoparticulate system. Did the author checked if they 
rather had micelles instead of particles? 
As reported in Figure 1, 100% of release in reached in 3000 min which correspond to 50 hours and is more 
concordant with a nanoparticles release. 
Curcumin is well known to degrade very fast at pH 7.4. The authors should explain how they could obtain 
100 % of release without any loss. 
As reported by the reviewer, curcumin rapidly decomposed at 37°C and pH 7.4. However, it is known that 
the stability of curcumin is significantly increased in serum added medium as in blood. Several studies 
recently confirmed the high affinity nature of curcumin binding to BSA [ Borsari, M., et al. 2002.  Inorg. 
Chem. Acta., 328, 61;  Barik, K. I. et al., 2003. Photochem. Photobiol., 77, 597] .The interaction with BSA has 
a double effect of solubilizing a higher number of molecules and simultaneously the unique ability in 
offering a strong protection from the oxidative and UV irradiation  damage. By this way, the condition 
selected for the study (PBS/FBS 50/50 v/v) assured Curcumin to keep stable in the release medium.  
 
The internalisation test using quantum dots is not described anywhere in the manuscript. Since it is a very 
important control experiment to validate the authors hypothesis, I would strongly recommend the authors 
to provide more conclusive data. 
 
As suggested by the reviewer, we insert the internalization study into the text. 
 
Some minor points: 
-the title is not appropriate since no targeting capability was tested in the manuscript 
We agree with the referee and change the title in: 
-Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt 
Abeta aggregates. 
 
-some graphics are not referenced in the the text. 
For example:Figure 1E, Table S1 and Fig S1 are not referenced anywhere in the text, so what am I suppose 
to understand with these data. 
We inserted referenced figures along the text 
 
-Some figure legends contain huge amount of information that should be included in the method section 
We re-write figure legends deleting or shifting information. More in detail, we deleted some parts 
describing results and statistical analyses where it described not-significant data. Some significant data 
were shifted in the text. 
 
Comments from the editor: 
1. Please make sure that the resolution of all figures, including the graphical abstract, is sufficiently high, 
and that all text and numbers are clearly visible. 
done 
 
2. As requested by reviewer #2, please shorten the figure legends. 
done 
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Abstract 
The formation of extracellular aggregates built up by deposits of β-amyloid (Aβ) is a hallmark 
of Alzheimer’s disease (AD). Curcumin has been reported to display anti-amyloidogenic 
activity, not only by inhibiting the formation of new Aβ aggregates, but also by 
disaggregating existing ones. However, the uptake of Curcumin into the brain is severely 
restricted by its low ability to cross the blood-brain barrier (BBB). Therefore, novel strategies 
for a targeted delivery of Curcumin into the brain are highly desired. Here, we encapsulated 
Curcumin as active ingredient in PLGA (polylactide-co-glycolic-acid) nanoparticles (NPs), 
modified with g7 ligand for BBB crossing. We performed in depth analyses of possible 
toxicity of these NPs, uptake, and, foremost, their ability to influence Aβ pathology in vitro 
using primary hippocampal cell cultures. Our results show no apparent toxicity of the 
formulated NPs, but a significant decrease of Aβ aggregates in response to Curcumin loaded 
NPs. We thus conclude that brain delivery of Curcumin using BBB crossing NPs is a 
promising future approach in the treatment of AD. 
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Introduction 
Alzheimer’s disease (AD) is the most common cause of dementia among an estimated 
prevalence of 46.8 million people worldwide suffering from some form of dementia in 2015 
(www.alz.co.uk/research/world-report-2016). Clinically, AD shows strong anterograde 
amnesia and a reduction of semantic knowledge. Furthermore, changes in personality and 
temper were reported (Butters et al., 1987). AD is a multi-factorial neurodegenerative 
disorder pathologically characterized by deposits of β-amyloid (Aβ) in senile plaques, 
intracellular neurofibrillary tangles (NFTs) comprised of hyper-phosphorylated aggregates of 
microtubule associated with tau protein, synaptic dysfunction, and neuronal death 
(Schellenberg and Montine, 2012; Perl, 2010; Gallo et al., 2007).  
The amyloid precursor protein (APP) is a transmembrane polypeptide of 770 amino acids. In 
its physiological form, it is known for neurotrophic activity, while in AD, a pathological 
deposition of a 42 amino acid long cleavage product of APP, Aβ1-42 occurs. Under 
physiological conditions, APP is processed into non-aggregating peptides by α-secretases. 
Genetic predisposition and/or environmental factors lead to differential processing of APP by 
β- and γ-secretases in AD (Vassar et al., 1999), which results in the formation of mainly 
extracellular Aβ aggregates. The Aβ monomers form dimers, oligomers, protofibrils and 
mature fibrils. Aβ modifications like phosphorylation have been shown to increase 
aggregation and toxicity (Kumar and Walter, 2011). 
Amyloid plaques are big and inhomogeneous aggregates of Aβ, other peptides, and also 
AGE’s (Advanced Glycation endproducts), which are built by non-enzymatic glycosylation. 
The plaques cause microglial activation and neuroinflammation. In addition or as result, 
synaptic loss is well described and has been attributed to a combination of toxic effects such 
as, among others, increased oxidative stress, synaptic Aβ toxicity, and/or zinc sequestration 
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by Aβ. Synaptic loss as well as a decrease in overall cell number both correlate strongly with 
cognitive impairment in AD (Butterfield, 1997). 
 
The diarylheptanoid Curcumin (Cur) is the main Curcuminoid found in the rhizome of the 
Turmeric/Curcuma longa plant. The root contains about 3-5 % Curcuminoids of which 
between 50-60 % are Cur with its main conformation (1,7-Bis-(4-hydroxy-3-methoxyphenyl)- 
hepta-1,6-dien-3,5-dion). A variety of physiological effects have been described for Cur in the 
last years. For example, Cur was reported to act as antioxidant due to its ability to neutralize 
radicals by two phenolic groups. Further, Cur has been shown to activate Nrf2 (Nuclear factor 
2) resulting in the increased expression of the antioxidant responsive element (ARE) 
(Esatbeyoglu et al., 2012). In addition, Cur has been shown to act anti-inflammatory by 
modulation of NfκB (Nuclear factor κB) signaling (Lin et al., 1997). Most importantly, Cur 
was reported to possess anti-amyloidogenic properties. Cur can not only inhibit the formation 
of new Aβ aggregates but also disaggregate existing ones (Yang et al., 2005). Additionally, 
increased neuronal cell viability and neurite formation was reported (Ray and Lahiri, 2009). 
Unfortunately, Cur displays a low bioavailability and solubility. To overcome these 
limitations, which strongly hamper the applicability in clinical use of Cur, different drug 
delivery systems were investigated as strategies to stabilize the active, to reduce its 
metabolism and to prolong its circulation within the body, thus achieving more bioavailable 
formulations of Cur. In fact, Cur was encapsulated in liposomes, solid lipid microparticles, or 
nanoparticles using both natural (i.e chitosan) or synthetic polymers (polylactide-co-
glycolide: PLGA, poly(n-butyl cyanoacrylate): PBCA). These nanoformulations were 
developed for preclinical studies on cancer, inflammation, wound healing, and other 
pathological conditions, which demonstrated enhanced therapeutic efficacies, when 
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nanoformulation strategies were applied in comparison with free Cur (Lazar et al, 2013; 
Subramani et al., 2017, Hussain et al., 2017).   
The properties of Cur against inflammation and oxidative stresses were also investigated with 
references to brain diseases, in which these events represent both a pathological hallmark and 
possible causes of the progression of the diseases. Above physico-chemical “negative” 
properties of Cur, another major issue, considering the application in brain diseases, consists 
of the poor penetration of Cur across the Blood-Brain Barrier (BBB) (Anand et al., 2007). 
The BBB describes the physiological barrier between the blood circulatory system and the 
central nervous system (CNS). The physiological function of the BBB is of major importance 
for maintaining a normal brain environment enabling the tight regulation of ion hemostasis 
and also protecting the CNS from circulating pathogens or toxins (Abbott et al., 2010). The 
development of new strategies to enhance Cur brain delivery based on colloidal carriers is of 
great importance, since engineered nanocarriers can protect drugs and deliver them across the 
BBB to target brain cells in a non-invasive way (Tosi et al., 2008).  To our knowledge, only 
few studies approached the formulation of Cur nanoparticles designed to target the brain. 
More in details nanoparticles functionalized with apolipoprotein E mimicking lipoprotein 
particles (Mulik et al., 2010) or surface engineered with Tat-1 peptide-derived from tetanus 
toxin (Mathew et al., 2012) were proposed as potential tools to transport Cur into the brain 
and tested in vitro.   
In our research paper, we proposed the application of a new technology for drug 
administration in the brain (Vergoni et al., 2009; Tosi et al., 2010), based on the formulation 
of biodegradable polymeric (PLGA) nanoparticles (NPs) loaded with Cur and modified with a 
glycopeptide (g7) able to cross the BBB (Costantino et al., 2005; Tosi et al., 2007; Tosi et 
al., 2011). Notably, both FDA and EMA approved PLGA in various drug delivery systems in 
humans (Mundargi et al., 2008), as confirmed by a number of marketed products (i.e., 
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Lupron Depot, Nutropin Depot). Here, Cur loaded PLGA g7-NPs were tested for toxicity, 
targeted delivery, and biological activity using an in vitro model for AD, thus opening the 
pave for the future applications in in vivo animal model for evaluation of the efficacy in AD 
management. 
 
Materials and Methods 
Materials 
Poly(D,L-lactide-co-glycolide) (PLGA,RG503H, MW near to 11,000) was used as received 
from the manufacturer (Boehringer-Ingelheim, Ingelheim am Rhein, Germany). Gly-L-Phe-
D-Thr-Gly-L-Phe-L-Leu-LSer(O-β-D-Glucose)-CONH2 (g7) was prepared as described 
previously and conjugated with PLGA to obtain g7-PLGA (Tosi et al., 2011; Vergoni, et al., 
2009; Costantino et al., 2005; Grabrucker et al., 2011a; Tosi et al., 2013). PLGA 
derivatization yields were confirmed by NMR, from the relative peak area of the signals at 
7.2–7.5 ppm, corresponding to the aromatic protons of the Phe present and from the multiplet 
at 1.80–1.60 ppm, corresponding to the protons of the methyl groups of the polymer, 
respectively, and resulted to be in the range of 30–40 μmol peptide/g of polymer.  
 Curcumin (Cur) was obtained by Sigma Chemical Co. (St. Louis Mo, USA). Polyvinyl 
alcohol (PVA), MW near to 15,000 Da was provided from Fluka (Milano, Italy). A Milli-Q 
water system (Millipore, Bedford, MA, USA), supplied with distilled water, provided high-
purity water (18 Ω) for NPs preparation. All the solvents were of analytical grade, and all 
other chemicals [ethyl(dimethylaminopropyl) carbodiimide (EDC), NHydroxysuccinimide 
(NHS), trehalose dihydrate (C12H22O11∙2H2O), 2-(N-morpholino) ethanesulfonic acid (MES)] 
were obtained commercially and used without further purification. 
Primary antibodies were purchased from Synaptic Systems (Bassoon), biorbyt (IκB), Sigma 
Aldrich (MAP2), Merck Millipore (OC), and Cell Signaling (PARP). Secondary Alexa Fluor 
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conjugated antibodies were purchased from Invitrogen. Secondary HRP conjugated 
antibodies were purchased from Dako. Synthetic Aβ peptide, human Aβ(1-42), was purchased 
from American Peptides (Sunnyvale, CA, USA) and AnaSpec Inc. (San Jose, CA, USA). 
Unless otherwise indicated, all other chemicals were obtained from Sigma-Aldrich.  
 
Methods 
Preparation of nanoparticles  
Cur loaded NPs (g7-NPs-Cur) were prepared by oil-in-water simple emulsion/solvent 
evaporation method as described in literature with some modifications in the preparation 
procedure (Mainardes et al., 2005; Bondioli et al., 2010). Briefly, a mixture composed by 
g7-PLGA (9 mg), PLGA (91 mg) and Cur (5 mg, 5% w/w dry weight of polymer) were 
dissolved in 3 mL of dichloromethane. The polymer/drug organic solution was emulsified in 
12 mL of 1% w/v aqueous solution of PVA under sonication (55 W for 60 sec) at 5°C. Then, 
the emulsion was mechanically stirred (1,500 rpm) for at least 3 h (RW20DZM, 
Janke&Kunkel, IKA-Labortechnik, Staufen, Germany) at r.t. until complete evaporation of 
the solvent. As control, empty (NPs) and empty functionalized nanoparticles (g7-NPs) were 
formulated applying the same technology. 
 
Purification and collection of the NPs 
All NPs preparations were purified by an ultracentrifugation process carried out at 17,000 rpm 
for 10 min (4°C; Sorvall RC28S, Dupont, Brussels, Belgium) to remove the un-formed 
material and the free surfactant fraction. The NPs were washed three times with water, re-
suspended in water (5 mL) and freeze-dried (-60°C, 1x10
-3
 mm/Hg; LyoLab 3000, Heto-
Holten) by using D-(+)-trehalose (Fluka–Sigma–Aldrich) as cryo-protectant (1:1 w/w 
polymer/trehalose ratio). The yield (Yield%) was calculate as follows: 
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Yield (%) = Sfd/Ctot x100 
 Sfd is the amount (mg) of freeze dried samples (excluded residual PVA and anhydrous 
trehalose) and Ctot is the total amount (mg) of polymer and Cur weighted  for the preparation. 
 
Atomic force microscopy  
Atomic force microscopy (AFM) was used to clarify the morphology of the samples. The 
atomic force microscopical observations were performed with an Atomic Force Microscope 
(Park Instruments, Sunnyvale, CA, USA) at about 20°C operating in air and in Non-Contact 
(NC) mode using a commercial silicon tip-cantilever (high resolution noncontact “GOLDEN” 
Silicon Cantilevers NSG-11, NTMDT, tip diameter = 5–10 nm; Zelenograd, Moscow, Russia) 
with stiffness about 40 Nm−1 and a resonance frequency around 170 kHz. After the 
purification, the samples were dispersed in distilled water and applied on a freshly cleaved 
mica disk (1 cm × 1 cm); 2 min after the deposition, the water excess was removed using 
blotting paper. The AFM images were obtained with a scan rate 1 Hz and processed using a 
program obtained from Gwyddion (Department of Nanometrology, Czech Metrology 
Institute, Brno, Czech Republic). Images were flattened using second-order fitting to remove 
[sample tilt] background curvature and slope from the images. 
 
Particle Size and Z-potential analysis  
The mean particle size (Z-average) and the polydispersivity index (PDI) were determined at 
r.t. by photon correlation spectroscopy (PCS) using a Zetasizer Nano ZS (Malvern, UK; Laser 
4 mW He–Ne, 633 nm, Laser attenuator Automatic, transmission 100–0.0003%, Detector 
Avalanche photodiode, Q.E. > 50% at 633 nm). The Z-potential (-pot) was measured using 
the same equipment with a combination of laser Doppler velocimetry and phase analysis light 
scattering (PALS). All the data are the means of the least three determinations carried out for 
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each preparation lot, referring to a suspension of NPs in distilled water before and after 
lyophilization. 
 
Determination of the amount of PVA residual  
As the residual PVA associated with the NPs could affect the physical properties and the 
cellular uptake, the amount of PVA was determined by a colorimetric method based on the 
formation of the colored complex between two adjacent hydroxyl groups of PVA and an 
iodine molecule (Joshi et al., 1979). Briefly, 5 mg of a freeze-dried sample were solubilized 
in 1 mL of DCM. Then, 2 mL of distilled water were added and the organic solvent was 
evaporated at r.t. under stirring (2 h). The suspension was filtered (cellulose nitrate filter, 
porosity 0.45 m, Sartorius, Firenze, Italy) to remove the polymeric residue and 1 mL of the 
aqueous solution was treated with 2 mL of 0.5 M NaOH for 15 min at 60°C. The solution was 
neutralized with 900 L of 1 N HCl and the volume adjusted to 5 mL with distilled water. 
Then, 3 mL of a 0.65 M solution of boric acid, 0.5 mL of a solution of I2/KI (0.05 M/0.15 M), 
and 1.5 mL of distilled water were added. PVA concentration was determined measuring the 
absorbance at 690 nm after 15 min incubation at r.t. in comparison with a standard plot of 
PVA prepared under the same experimental conditions. 
 
Determination of drug loading capacity and encapsulation efficiency 
Cur loaded into g7-NPs-Cur was extracted and quantified by high performance liquid 
chromatography (HPLC). Briefly, an exact amount of NPs (about 1 mg) was solubilized into 
0.5 mL of chloroform by using a bath sonicator for 5 min. Then, 4 mL of isopropylic alcohol 
were added to precipitate the polymer. The mixture was filtrated through PTFE filter (0.2 
mm, Sartorius, Firenze, Italia) and the solution analyzed by HPLC. The HPLC apparatus 
(JASCO Europe, Cremella, Italy) comprised a Model PU2089 pump provided with an 
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injection valve with a 50 L sample loop (Model 7725i, Jasco) and the UV/VIS detector 
(UV1575, Jasco). The analysis was performed in isocratic conditions, at a flow rate of 1 
mL/min and at r.t. on a column HC-C18 (250mm x 4.60 mm, 5 um, Agilent Technologies) 
equipped with a security guard. The mobile phase was a mixture 41:23:36:1 (v/v/v/v) of 
acetonitrile, methanol, water and acetic acid. Chromatographic peak areas of the samples 
were recorded and analyzed using a JASCO software (JascoBorwin 1.5) and the concentration 
was calculated using the calibration curve previously set up (linearity was assumed in the 
range 0.3–9.5 g/mL; r2 = 0.9951). The encapsulation ability of NPs was evaluated 
considering the encapsulation efficiency (EE%) and the loading capacity (LC%) calculated 
using the following equations: 
EE% = D/ Td ×100 
LC% = D/ W × 100 
where D is the amount of the encapsulated drug, Td is the amount of drug added for the 
preparation and W is the weight of NPs (polymer + drug). 
All the data are expressed as the mean of at least three determinations. 
 
In vitro release studies 
For each time point, an exact amount of g7-NPs-Cur (about 2 mg) was suspended in 1 mL of 
a 50% v/v of serum solution (FBS) at 37°C under electromagnetic stirring. After the 
incubation time (30 min, 3, 6, 24, 30, 48, 72 h), the suspensions were centrifuged (13,000 rpm 
for 15 minutes) to separate NPs (with possible adsorbed serum protein and residual loaded 
Cur) that precipitates from supernatant. The possible serum proteins adsorbed on NPs surface 
were quantified by colorimetric assay bicinchoninic acid (BCA) as described by manufacturer 
(Micro BCA protein assay kit composed of reagent A (alkaline tartrate-carbonate buffer), 
reagent B (bicinchonic acid solution) and reagent C (copper sulfate solution), purchased from 
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Thermo Fisher Scientific Inc (Milan, Italy)) and subtracted from dried pellet to obtain the 
amount of NPs recovered after centrifugation. Residual Cur in NPs was extracted and 
quantified from pellet as described above.  
 
Cell culture 
Primary hippocampal cultures were prepared from rat brains (embryonic day 18) as described 
before (Grabrucker et al., 2009). In brief, the brains were collected in pre-chilled Hank's 
balanced salts solution (HBSS, GE Healthcare Life Sciences, UK) and the hippocampi were 
dissected. Hippocampi in 1800 μL HBSS were then trypsinized with 200 μL Trypsin 2.5% 
(Invitrogen, USA) for 20 min at 37°C. After 5 washing steps, cells were re-suspended in 1600 
μL HBSS and 400 μL DNAse 1 (0.01%). The suspension was filtered through a 125 μm sieve 
and incubated with 18 mL of DMEM (Dulbecco's Modified Eagle Medium, GIBCO, USA), 
10% FCS, 1% glutamine and 1% penicillin-streptomycin. Cells were then counted in the 
Neuburger-Chamber. After preparation, the hippocampal neurons were seeded on poly-l-
lysine (0.1 mg/mL; Sigma-Aldrich) glass coverslips in a 24 well plate at a density of 30,000 
cells/well or 10 cm petri dish at a density of 3 x 10
6 
cells/dish.
 
Cells were grown in 
Neurobasal
TM
 medium (Life Technologies), complemented with B27 supplement (Life 
Technologies, USA), 0.5 mM L-Glutamine (Life Technologies) and 100 U/mL 
penicillin/streptomycin (Life Technologies) (resulting in NB+++ medium) and maintained at 
37°C in 5% CO2. All animal experiments were performed in compliance with the guidelines 
for the welfare of experimental animals issued by the Federal Government of Germany and by 
the local ethics committee of Ulm University (ID Number: O.103). 
Treatment of hippocampal cells 
Aβ(1-42) peptides were initially dispersed in dH2O at a concentration of 1 mg/mL and 
thereafter stored at -20°C until use. Further dilutions of the peptides were performed in the 
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culture medium (NB+++). Pure Cur was diluted to 1 mM in DMSO and stored at -20°C. 
Further dilutions were performed in the culture medium (NB+++). To carry out the treatment 
with NPs, neurons were seeded in a total volume of 500 l per well (24 well plate) or 10 mL 
per 10 cm petri dish in NB+++ medium. Freeze dried NPs samples were re-suspended in 
HBSS under sonication (Emmi-05P Sonicator, Emag, Germany) to have a starting batch for 
further dilution in culture medium (NB+++) to administer different concentration (10, 20, 40 
M final concentration) of Cur by NPs in cells. NP stock solutions were prepared according 
to the calculated Cur content and the volume of HBSS adjusted accordingly. Stock solutions 
of empty NPs were prepared to match the amount of NP per mL of Cur loaded NPs. 
 
Immunocytochemistry 
For immunofluorescence, the primary cultures were fixed with 4 % paraformaldehyde (PFA)/ 
4% sucrose/PBS at 4°C for 20 min and processed for immunocytochemistry. After washing 
3x5 min with 1x PBS containing 0.2% Triton X-100 at RT, blocking was performed with 
10% FBS/ 1x PBS for 1 h at r.t. Subsequently, samples were incubated with primary antibody 
at r.t. for 2 h or at 4°C overnight. After a 3x5 min washing-step with 1x PBS, incubation with 
the secondary antibody coupled to Alexa488, Alexa568 or Alexa647 followed for 1 h. Cell 
nuclei were counterstained with DAPI and coverslips subsequently mounted using Vecta 
Mount (Vector Laboratories, USA). 
 
Determination of cell death (apoptosis versus necrosis)  
Toxicity of the samples after treatment was characterized by a healthy/apoptotic/necrotic cell 
detection kit (Promokine, Germany) using primary hippocampal rat cultures at DIV 14 on 24-
well plates (in 500 L medium per well), according to the manufacturer’s protocol. In brief, 
cells were washed with 1x binding buffer and incubated for 15 min at r.t. protected from light 
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with a staining solution containing 100 μL of 1x binding buffer, 5 μL of FITC-Annexin V, 5 
μL of Ethidium Homodimer III and 5 μL of Hoechst 33342. Cells were washed twice with 1x 
binding buffer. Then, the cells were fixed with (PFA)/PBS and 1.25 mM CaCl at r.t. for 15 
min. Coverslips were mounted on slides with a drop of Vecta Mount. As positive control, 
apoptosis was induced with 500 μL of 70% ethanol. 
 
Protein Biochemistry 
Treated primary hippocampal rat cultures at DIV 14 were lysed and homogenized in lysis 
buffer (150 mM NaCl, 1% Triton® X-100, 50 mM Tris HCl, pH 8.0) containing protease 
inhibitor (Roche, Mannheim, Germany) at 4°C for 2-3 h by overhead shaking before being 
centrifuged for 15 min at 3,200 x g. Experiments were performed in Petri dish. The resulting 
supernatant was then used for analyses. Subcellular fractions were isolated as described 
previously with minor modifications (Schmeisser et al., 2012). To detect the fibrillation state 
and concentration of Aβ in the supernatant, Ultra Centrifugal Filters from Amicon (Germany) 
were used to increase the sample concentration. 500 μl of the supernatant were loaded into a 
filter and spun with 14,000 rpm for 10 min. The filter was then placed upside down in a new 
tube and spun again with 1,000 rpm for 10 min.  
Western blotting: For western blot experiments, membrane-associated fractions from rat 
brains (P2) were used. Proteins were separated by SDS-PAGE and blotted onto Nitrocellulose 
membranes. Immunoreactivity was visualized using HRP-conjugated secondary antibodies 
and the SuperSignal detection system (Pierce, Upland, USA). 
Dot blotting: For Dot blots experiments, a PVDF membrane was incubated with 100% 
methanol followed by water for few seconds and subsequently with Transfer Buffer + SDS 
for 3 min. Three dots for each protein sample, corresponding to 3 μg of protein, were put on 
the membrane and incubated over night. The membrane was washed twice with TBST 0.05% 
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and incubated with Blocking Solution for 30 min at r.t. on a shaker. Then, incubation of the 
membrane with the OC antibody (primary antibody) diluted 1:1000 in Blocking solution for 2 
h at r.t. was performed. Subsequently, 4x 5 min washing-steps with TBST 0.05% were 
followed by the incubation with the secondary antibody (Dako, Glostrup,) diluted 1:1000 in 
Blocking solution at r.t. for 1 h. After 4x 5 min washing-steps with TBST 0.05%, the 
immunoreactivity was visualized using Pierce ECL Western Blotting substrate 
(ThermoScientific, USA). Images were obtained by a MicroChemi Imaging System from 
Biostep.  
 
Aβ aggregation assay 
Aβ aggregation was determined using a Thioflavin T Beta-Amyloid (1-42) Aggregation Kit 
(SensoLyte, AnaSpec) according to the manufacturer’s instructions. In brief, 900 μL of the 
assay buffer were added to 100 μL of Thioflavin to get a 2 mM solution. Aβ peptide was 
diluted in 1 mL of cold assay buffer and sonicated for 5 min, followed by centrifugation at 
10,000 rpm for 5 min at 4 °C. To set up the fibrillation reaction, 10 μL of 2 mM Thioflavin 
were added into each well. Then, 85 μL of the Aβ solution and 5 μL of the test compounds 
(NPs) or control were added. As a control for pure Cur, DMSO was used. As control for the 
NPs, assay buffer was used. The fluorescence intensity was measured at 37°C with an 
excitation of 440 nm and an emission of 484 nm using a microplate reader (Tecan Infinite 
PRO 200, Tecan, Switzerland) every 10 min for up to three hours.  
 
Determination of oxidative stress 
Oxidative stress was measured using the CellROX
® 
Oxidative Stress detection kit (Thermo 
Fisher) according to the manufacturer’s instructions. CellROX® oxidative stress green 
reagents were used to show possible antioxidant properties of Cur and Cur loaded NPs in 
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primary hippocampal rat neurons at DIV 14. In brief, CellROX
®
 green reagents were added to 
cells at a concentration of 5 μM and cells incubated for 30 min at 37°C. Medium was 
removed and cells were washed 3 times with PBS. Cells were fixed in 4% PFA/4% 
sucrose/PBS for 15 min at r.t.. Fluorescence was measured from CellROX
®
 green reagents at 
520 nm being the oxidized form while CellROX
®
 green reagents shows significantly less 
fluorescence in the reduced state. Oxidative stress was induced in vitro to serve as positive 
control for the CellROX
®
 kit and to test for a rescue with Cur. Fenton’s reagents were applied 
overnight on a 24 well plate. 0.5 μM of FeCl2 and 2.5 μM of H2O2 were added. The 
dissociated Fe
2+ 
ions are able to oxidize while reducing H2O2 to one Hydroxide ion and one 
Hydroxyl radical (Fe
2+
 + H2O2  Fe
3+
 +HO
-
 + HO). 
 
Statistics 
Statistical analysis was performed with SPSS version 20. All data are shown as mean ± SEM. 
For comparisons, one-way analysis of variance (ANOVA) was performed followed by post 
hoc tests for within group comparisons (Bonferroni test). Statistically significant differences 
are indicated in the figures by * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001. 
Immunocytochemistry - Acquisition and evaluation of all images were performed under 
“blinded” conditions. 10 cells of each condition were imaged. All signals within the optic 
fields were quantified in the following way: Fluorescence images were obtained with an 
upright Axioscope microscope equipped with a Zeiss CCD camera (16 bits; 1280x1024 ppi) 
using Axiovision software (Zeiss). Quantification was performed using ImageJ 1.49o. 
Western blot quantification - Evaluation of bands was performed using ImageJ. Three 
independent experiments were performed. The individual bands were selected and the 
integrated density was measured. Bands were normalized to β-actin and the ratios averaged 
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and tested for significance. For Dot blot quantification, signals of individual spots were 
selected and the integrated density was measured.  
Results 
Formulation and characterization of novel nanocarriers 
The chemico-physical and technological characterization of samples is reported in Fig. 1. All 
NPs were characterized in terms of size, surface charge, residual amount of surfactant and 
yield of preparation. All samples, independently of functionalization and/or loading, were 
featured by the hydrodynamic diameters (Z-average) around 200-250 nm and relatively 
narrow size distributions (polydispersivity, PDI<0.1), favorable for a systemic administration 
(Fig. 1A). Un-modified NPs exhibit high negative value of ζ-pot (-22 mV) owing to the 
exposure of the carboxylic group of PLGA that indicates high electric charge on the surface 
of the NPs, which is responsible for the strong repulsive forces amongst the particles that 
prevents their aggregation in water. The functionalization with g7 (g7-NPs) significantly 
alters the ζ-pot value of NPs, reducing the negativity of their surface (about -13 mV); g7-NPs-
Cur maintained the surface charge of g7-NPs, suggesting the absence of drug adsorbed on the 
NP surface. The amount of residual surfactant was less than 8% of the total formulation mass 
and compatible with parenteral administration (Fig. 1A). ESCA analysis, a versatile tool in 
identifying the chemical species on the surface of nanoparticles (Ratner et al., 2009), was 
applied. Since all materials forming nanoparticles (PLGA, PVA and Cur) are composed of 
few atoms (namely C, H and O), the identification of N signal, typical of g7 peptide, are 
routinely considered as a strong proof of success of the surface engineering procedure. The 
atomic spectra of the engineered NPs, (g7-NPs and g7-NPs-Cur) in comparison with plain 
NPs showed N signals indicating that the location of g7 is on the surface of NPs (Fig. 1B).  
AFM images of samples (g7-NPs and g7-NPs-Cur) (Fig. 1C) showed a defined and 
reproducible spherical morphology and smooth surface already observed for un-modified NPs 
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(data not shown). The AFM diameters were in agreement with PCS data. The presence of 
residual surfactant could be responsible of some aggregation during the dehydration process 
(necessary for the analyses). All samples show a yield between 85 and 95%, which can be 
considered satisfactory.  
From a technological point of view, g7-NPs Cur showed high drug loading capacity (LC) of 
about 3% (w/w) and an encapsulation efficiency (EE) of about 60% (Fig. 1A). The release 
profile of Cur from NPs in simulated physiological condition (PBS buffer added of 50% v/v 
of serum, in respect of sink conditions) is reported in Fig. 1D. We observed an initial massive 
“burst release” (about 60-70%) followed by a second slow release phase. These data suggest 
the presence of a significant amount of drug in the outer part of the structure, able to rapidly 
diffuse into the medium. Cur incorporated in the core of NPs was completely diffused within 
72 h probably as a consequence of the beginning of NPs degradation.  
Additionally, we characterized the g7-NPs-Cur according their photo-physical proprieties 
(Fig. 1E). After excitation at 405 nm, these NPs showed a large emission with a maximum at 
510 nm, typical of Cur.  
 
g7-NPs-Cur show no cell toxicity 
In a first set of experiments, we evaluated whether the novel g7-NPs (loaded/unloaded) exert 
toxic effects on hippocampal neurons in vitro. To that end, we tested the same amount of g7-
NPs and g7-NPs-Cur. Fixed amounts of NPs (namely 46, 115 and 230 g of g7-NPs or g7-
NPs-Cur), corresponding to the concentration of 10, 20 and 40 M of Cur in g7-NPs-Cur 
were applied to neurons at DIV 13 and the rate of apoptosis and necrosis was measured after 
24 h (Fig. 2A). Irrespective of the concentration used, no significant increase in apoptotic 
cells was detected after 24 hours. Selecting a NPs concentration delivering at least 20 M Cur 
and various incubation times from 1 h to 7 d, similarly, no increase of apoptotic cells was 
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visible (Fig. 2B). To investigate, whether NPs induce necrosis rather than apoptosis, we 
applied again concentrations of NPs delivering at least 20 M Cur and evaluated the rate of 
necrosis after 24 h (Fig. 2C) and 7 d (Fig. 2D) of treatment using a healthy/necrotic cell 
detection kit. Necrotic cells were detected by ethidium homodimer III staining and the total 
number of cells was assessed using Hoechst 33342 labeling all nuclei. No significant increase 
in necrotic cells was detected. As expected, ethanol (70%), used as positive control, induced a 
significant increase of necrosis (one-way ANOVA: F = 5.419, p < 0.001; Bonferroni post hoc 
p = 0.005 after 24 h and one-way ANOVA: F = 3.067, p = 0.012; Bonferroni post hoc p = 
0.023 after 7d). 
 
g7-NPs-Cur uptake into neurons 
As proof of the affinity of g7-NPs-Cur to neurons, we investigated the cellular uptake by 
means of fluorescence analysis (Fig.3).  Since Cur is characterized by large emission spectra 
which could interfere with signals derived from immunocytochemistry, in order to minimize 
the interference, we selected as fluorocromes, very strong imaging tools (namely QDs), 
featured by a very unique and defined signal. Therefore, g7-(QD)-NPs-Cur (see 
supplementary for information regarding the formulation, Table S1 and Fig S2 for 
characterization) were incubated with neurons for 3 hr. Data reveled that, on average, 75% 
(data not shown) of the intracellular nanoparticles co-localized with Clathrin positive signals 
and we could claim that this output strongly agree with previous published data which 
described the cellular interaction of g7-NP (unloaded) (Vilella et al., 2015) mediated by 
clathrin pathways. Moreover, this result is also underlining the fact that the presence of even 
little amounts of Cur adsorbed onto the NPs surface did not interfere with the efficiency and 
dynamic of cells interaction. 
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Increased levels of Cur do not result in cellular toxicity 
As previously evidenced, after exposure of cells to Cur loaded g7-NPs, the g7-NPs are readily 
taken up into cells. The resulting increase in intracellular and extracellular Cur concentration 
did not produced significant increase in cell death after 24 h and up to 7 d (Fig. 4A) even if 
high Cur concentrations (up to 200 M) were used. The most suitable and efficient 
therapeutic concentration of Cur was indicated to be around 10 M (Goozee et al., 2016) on 
cellular level. Therefore, in further experiments, this concentration was used. As additional 
readout, to investigate whether Cur, g7-NPs or g7-NPs-Cur induce mechanisms of cell death 
not readily detectable on cellular level but on molecular level, we analyzed poly(ADP-ribose) 
polymerase (PARP). The enzyme caspase-3 can be activated both by extrinsic and intrinsic 
pathways and contributes to the proteolytic cleavage of key proteins involved in cellular 
apoptosis, such as the nuclear enzyme PARP (Salvesen, 2002). Thus, the amount of cleaved 
PARP is indicative of programmed cell death (Virág et al., 2013). However, we could not 
detect a significant increase in cleaved PARP in hippocampal neurons treated with Cur or g7-
NPs after 24 h (Fig. 4B) and 7 d (Fig. 4C) of treatment. 
One proposed action of Cur is to act as scavenger of free radicals and thus reduce oxidative 
stress (Rajeswari, 2006). Therefore, in a next set of experiment, we induced oxidative stress 
by addition of H2O2 and FeCl2 (Fenton reaction) (Fig. 4D and 4E). One day after the 
treatment, oxidative stress was measured by CellRox
®
 staining. Neurons showed a significant 
increase of oxidative stress after treatment compared to untreated cells (one-way ANOVA: F 
= 8.554, p < 0.001). However, cells treated for 30 min and 1 day with Cur did not present 
such an increase. Cur also acted on untreated control cells hinting towards a reduction of 
oxidative stress endogenously present in control cultures (Fig. 4D) (Bonferroni post hoc test 
revealed significant differences between control and control with increased oxidative stress, 
and all Cur treatment groups p < 0.001) Delivery of Cur by g7-NPs had the same protective 
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effect even after 7 d of treatment (Fig. 4E) (one-way ANOVA: F = 18.542, p < 0.001; 
Bonferroni post hoc test revealed significant differences between control and control with 
increased oxidative stress, and control and g7-NPs-Cur treatment groups p < 0.001). 
 
Modification of Aβ pathology by Cur loaded g7-NPs in vitro 
Given the promising activity of Cur regarding oxidative stress and Aβ disaggregation (Yang 
et al., 2005), in a next set of experiments, we evaluated whether Cur and Cur delivered by g7-
NPs indeed was able to influence the cellular pathology induced by the presence of Aβ 
peptides in vitro. To that end, we incubated primary hippocampal neurons with 1, 10 and 100 
µM of monomeric Aβ for 24 hours and confirmed a significant effect on cell viability after 
exposure of cells to 10 and 100 µM Aβ (Fig. 5A). Ethanol was used as positive control (one-
way ANOVA: F = 6.139, p < 0.001; Bonferroni post hoc test revealed significant differences 
between control vs. EtOH control p = 0.003; control vs. Aβ10µM p = 0.07; control vs. Aβ100µM 
p = 0.0002). Next, we investigated whether this effect on cell health can be modified by 
additional exposure of cells to Cur and g7-NPs-Cur (Fig. 5B). Our results show that after 7 d 
of treatment, exposure of cells to Aβ again leads to a reduction in cell health. The addition of 
Cur or g7-NPs-Cur to these cultures partly restores cell health (seen as trend) (Fig. 5B).  
To answer the question, whether a positive effect of Cur is realized via altered Aβ aggregation, 
we again treated neurons with 100 µM Aβ and Cur and Cur delivering g7-NPs. After 7 d, the 
cell culture medium containing extracellular Aβ aggregates was removed and analyzed by 
native Western Blot and anti-Aβ labeling (Fig. 5C). A reduction in higher order Aβ 
aggregates was visible in conditions with exposure to Cur. 
To confirm the reduction in Aβ aggregates by g7-NPs-Cur, we performed a thioflavin T based 
ELISA assay. An increase of fluorescence signal is correlated with an increase of Aβ42 fibril 
formation. As control, inhibitors of Aβ aggregation (Morin/Phenol Red) were used (Fig. 5D). 
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The results show that co-incubation of Aβ with g7-NPs-Cur leads to a significant reduction of 
the observed Aβ aggregation and disaggregation was observed (one-way ANOVA: F = 
166.839, p < 0.0001; Bonferroni post hoc test revealed significant differences between all 
groups p < 0.001). Moreover, unloaded g7-NPs increased Aβ aggregation at short time. This 
finding is not surprising since, as described by Radic and coworkers (Radic et al., 2015), 
nanoparticles, in function of both their properties and the experimental conditions 
(concentration, ratio with A peptides etc) could be able to initially attract peptides promoting 
A aggregation onto the NP surface due to increased local protein concentration on the 
surface and destabilization of the folded state. However, at longer time-points, a further 
increase in NPs-peptide attraction could lead to a decrease of amyloid fibrils stability and to a 
reduction of their lateral diffusion on the NP surface, necessary for peptide conformational 
changes and self-association, thus prohibiting amyloid aggregation. 
To further verify these findings, we used Aβ conformation dependent antibodies (OC 
antibody) that specifically recognize distinct assembly states of amyloids, including 
prefibrillar oligomers and fibrils. The OC antibody is able to recognize fibrillary oligomers 
that are immunologically distinct from prefibrillar oligomers (Kayed et al., 2007). Dot blot 
analysis shows the presence of fibrillary oligomers in all cultures exposed to Aβ. As indicated 
by the previous results, the immune-reactive signal of OC antibody is significantly reduced by 
treatment with Cur and g7-NPs-Cur (Fig. 5E) again hinting towards a reduced aggregation 
and/or disaggregation of Aβ (one-way ANOVA: F = 91.639, p < 0.0001; Bonferroni post hoc 
test revealed significant differences between all groups and the Control p < 0.001; Moreover a 
significant difference is detected between Aβ and Aβ + Cur p = 0.049, and Aβ + g7-NPs-Cur 
p < 0.001). 
Further, we detected that the number of Aβ positive signals per area was significantly reduced 
in cultures treated with Cur loaded g7-NPs 7d after incubation with 10 µM of monomeric Aβ 
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and g7-NPs (Fig. 5F) (one-way ANOVA: F = 34.493, p < 0.0001; Bonferroni post hoc test 
revealed significant differences between Aβ and Aβ + Cur p < 0.001, and Aβ + g7-NPs-Cur p 
< 0.001). 
The NF-κB (nuclear factor 'kappa-light-chain-enhancer' of activated B-cells) pathway is 
important for the expression of many genes involved in inflammatory response and the 
constitutive activation of the pathway is associated with AD (Yamamoto and Gaynor, 2004). 
NF-κB is controlled by a family of inhibitory proteins known as IκB, which include IκBα, 
IκBβ, IκBϵ and IκBγ. IκB thereby inhibits NF-κB. Therefore, new therapeutic targets that 
prevent the aberrant activation of NF-κB might be promising in AD. As it was previously 
reported that Cur analogs act as NF-κB inhibitor (Kasinski et al., 2008), and that Cur 
decreases the phosphorylation of IκB, we next assessed the ability of g7-NPs-Cur to influence 
IκB. To that end, we measured the signal intensity of IκB staining to generate an indirect 
read-out of IκB influences on NF-κB (Fig. 4G). Our results show that the fluorescence 
intensity of IκB immunoreactive signals is decreased after treatment of neurons with Aβ. In 
contrast, application of Cur as solution or delivered by g7-NPs-Cur was able to prevent this 
decrease (one-way ANOVA: F = 4.242, p < 0.001; Bonferroni post hoc test revealed 
significant differences between Aβ and Aβ plus g7-NPs-Cur treated cells p = 0.002, and 
between Aβ plus g7-NPs and Aβ plus g7-NPs-Cur treated cells p = 0.021).  The level of IκB 
immunoreactivity was even higher (seen as trend) as in controls upon treatment with Cur and 
g7-NPs-Cur independent of the presence of Aβ hinting towards a general mechanism of Cur. 
Finally, as the loss of synapses may be the best cellular correlate to the cognitive impairments 
observed in AD patients, we assessed the ability of g7-NPs-Cur to prevent the decrease in 
synapse density observed after exposure of neurons to Aβ (Grabrucker et al., 2011b). The 
mean number of synapses (Bassoon immunoreactive puncta) per dendrite length was 
measured 7 d after treatment with 10 µM Aβ (Fig. 5H). As expected, a reduction can be 
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observed in neurons exposed to Aβ. Interestingly, although not significant, a trend towards a 
rescue is observed in neurons treated with g7-NPs-Cur. 
 
Discussion 
Extracellular and intracellular protein aggregates are disruptive for synaptic function and cell 
health and are broadly held to be the major culprit of brain dysfunction underlying AD. 
Developing treatment strategies aiming to reduce protein aggregation and propagation are 
therefore highly desired goals. 
The use of innovative drug delivery systems engineered on their surface to pass the BBB 
offers a non-invasive tool for CNS drug delivery. Previously, we have yet demonstrated that 
surface engineered NPs made of a FDA-approved polymer are able to both stabilize active 
compounds with different molecular weights and to cross the BBB after systemic 
administration in wild-type and knockout rodents (Grabrucker et al., 2016, Salvalaio et al, 
2016, Valenza et al., 2015). Here, we developed a new generation of NPs potentially able to 
modify Aβ aggregates within the brain (g7-NPs-Cur). By that, we delivered Cur, a novel 
compound identified to be able to interfere with Aβ aggregation. Our in vitro data shows that 
g7-NPs-Cur are non-toxic for cells in concentrations delivering 10 M Cur. Moreover, g7-
NPs-Cur are able to reduce oxidative stress and to inhibit Aβ aggregation as well as to 
promote Aβ disaggregation more efficiently with respect to un-loaded free Cur. Taken 
together, our data clearly demonstrated a superior ability of g7-loaded nanoparticles to 
increase the cellular affinity of the active for neuronal cells. 
Interestingly, Cur binds to copper and zinc ions, but only weakly to zinc ions (Baum and Ng, 
2004) suggesting that Cur is able to decrease inflammatory damage by preventing metal 
induction of NF-κB (Mishra and Palanivelu, 2008) and Cur was reported to decrease IκB 
phosphorylation that leads to a reduced inhibition of NF-κB. Here, we were further able to 
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confirm a modulatory role of Cur delivered by NPs on the IκB complex. The loss of IκB that 
was observed in presence of Aβ aggregates was absent in cells treated with g7-NPs-Cur. Thus, 
it is indeed possible that Cur ameliorates inflammatory processes in AD brains. 
In conclusion, reduced oxidative stress, inflammation and plaque load are the major outcomes 
observed in in vitro experiments confirming that the g7-NPs-Cur provided an efficient 
delivery for loaded Cur and proved a promising carrier candidate for treating AD.  
Although further conclusions can be drawn only after a complete in vivo study in AD animal 
models, the results of this preliminary study suggest the potential role of surface modified 
loaded nanoparticles in stabilizing Cur, potentially solving the problem of administration and 
potentiating the effect of Cur against Aβ related toxicity.  
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Figure legends: 
Figure 1: Characterization of NP samples. (A) Chemico-physical parameters of samples. Z-Average, PDI 
(polidispersivity index) and -pot (Zeta Potential) of NPs in distilled water after the purification process. The 
percentage of encapsulation efficiency (EE) was determined as the ratio of the encapsulated out of the total 
(encapsulated + free) drug per cent (%). The percentage of loading capacity (LC) was expressed as the ratio of 
the encapsulated drug out of the total mass (encapsulated drug + lipids and/or polymer) per cent. The percentage 
of Yield was expressed as the ratio of the recovered freeze-dried sample (excluded residual PVA) out of the total 
mass weighted (polymer and drug) per cent. ESCA: Electron Spectroscopy for Chemical Analysis. All the values 
represent the means of at least three experiments; standard deviation (SD) in parentheses. (B) Examples of 
spectra recovered by ESCA. (C) AFM images of samples (g7-NPs and g7-NPs-Cur) were analyzed to obtained 
the height profile and diameter of particles. (D) Profile of drug release for g7-NPs-Cur obtained in simulated 
physiological condition (PBS buffer added of 50% v/V of serum). E) Photo physical characterization of g7-NPs-
Cur obtained by confocal microscopy after excitation at 405 nm. 
 
Figure 2: Evaluation of possible cell toxicity of NPs. (A) At DIV 13, cells were incubated with three different 
concentrations of loaded nanoparticles ranging from 46 to 230 µg for 24 hours . (B) Incubation of neurons with 
115 µg of g7 NPs-Cur for 1 h, 24 h and 7 d. (C,D)  Healthy/necrotic percentage of cells measured after 24 h (C) 
or 7 d (D) using a cell detection kit. Results were normalized against the untreated control. Ethanol (70%) was 
used as positive control. All analyses were performed by investigating 10 optic fields of view (n=10).  
 
Figure 3: QDs modified Cur loaded NPs are taken up into cells. At DIV 13, cells were incubated with 20 µg 
of labeled g7-NPs-Cur (g7-(QDs)-NPs-Cur) for 3 hours. Hippocampal neurons were stained for DAPI (blue) (A) 
and clathrin (green) (B). g7-(QDs)-NPs-Cur were visualized as red spot (C). Neurons were visualized by Map2 
staining (cyan) (D). E shows a merged image of signals.    
 
Figure 4: Increased levels of Cur do not result in cellular toxicity. (A) Toxicity after treatment with Cur  
after 24 h or 7 d. All analyses were performed by investigating 10 optic fields of view (n=10). (B, C) Western 
Blot and the expression/cleavage of Parp detected in hippocampal neurons treated with 10 µM of encapsulated 
Cur for 24 h (B) and 7 d (C). (D-E) Oxidative stress was induced by addition of H2O2 and FeCl2 (Fenton 
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reaction). Oxidative stress after treatment with Cur (D) or g7 nanoparticles (E) was measured by CellRox 
staining.  
 
Figure 5: Modification of Aβ pathology by Cur loaded g7-NPs in vitro. (A) Primary hippocampal neurons 
were incubated with 1, 10 and 100 µM of monomeric Aβ for 24 hours. Ethanol was used as positive control. All 
values were normalized to the untreated control. (B) cell viability of neurons  treated with 46 g of 
Nanoparticles corresponding to 10 µM of loaded Cur for 7 d. The cells were additionally exposed to 10 µM Aβ. 
(C) Western blot of extracellular Aβ aggregates after 7 d of treatment with Cur free or loaded into g7-NPs-Cur.  
(D)  Thioflavin T ELISA assay. (E) Dot blot analysis of the OC antibody in supernatants of cell cultures exposed 
to Aβ. OC signals were normalized to Ponceau S signals of the corresponding dot. Analysis was performed in 
triplicates. (F) Primary hippocampal neurons were incubated with 10  µM of monomeric Aβ and 46g of 
Nanoparticles to obtain a final concentration of 10 µM Cur for 7 d. Aβ aggregates were visualized by 
immunocytochemistry (green signal). Neurons were stained for MAP2. The number of Aβ positive signals per 
area was measured in ten optic fields per condition.  (G) The fluorescence intensity of IκB immunoreactive 
signals was measured in at least 10 cells per group. (H) The mean number of synapses per dendrite length 
(primary and secondary dendrite) was measured 7 d after treatment with 10 µM of monomeric Aβ. Synapses 
were visualized by staining for Bassoon.  
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